ANZCTR search results

These search results are from the Australian New Zealand Clinical Trials Registry (ANZCTR).

You can narrow down the results using the filters

34128 results sorted by trial registration date.
  • Phase I, open-label, sequential-group, three-cohort study to evaluate the pharmacokinetic profile, the safety and the tolerability of a single injection of lanreotide Extended-Release Formulation (ERF) at doses of 120 mg and 240 mg in healthy volunteers

    Study approved by bellberry ethics committee K on 19th February 2024. This is a single-centre, single ascending dose study to assess the safety of lanreotide Extended-Release Formulation, and how this drug acts in the body in healthy volunteers. Lanreotide may be indicated for use in patients with neuroendocrine cancer, but a trial of the drug in healthy volunteers is needed before trials in cancer patients can proceed. Who is it for? You may be eligible for this study if you are aged 18 to 55 years and are in good general health without a clinically significant medical history. People who have been diagnosed with cancer will not be eligible for this study. Participants who choose to enrol in this study may be enrolled into one of three dose cohorts. Healthy volunteer participants may receive either a single dose of lanreotide ERF administered as a subcutaneous (under the skin) injection or a single dose of lanreotide ERF administered as an intramuscular (into a muscle) injection. All participants will have their vital signs checked and will provide blood samples for testing. It is hoped this research will determine the maximum dose and best injection method for lanreotide ERF that can be administered safely without causing severe reactions. Once the dose of lanreotide ERF has been determined in healthy volunteers, a trial investigating the efficacy of lanreotide ERF as a treatment for neuroendocrine cancer patients may proceed.

  • Stepping towards precision rehabilitation; Establishing potential benefits and safety of early cardiac rehabilitation in diabetics post acute coronary syndrome

    Cardiovascular disease is the leading cause of death and disability among adults globally. In Australia it is the lead contributor to health care expenditure and with an ageing population the burden of disease is expected to increase. Cardiac rehab is an effective secondary prevention tool post acute coronary syndrome acute coronary syndrome but is underutilised and inconsistently delivered. The trial will whether early cardiac rehabilitation in high-risk acute coronary syndrome results in greater functional improvement at 6 months when compared to later and standard of care, examine the safety of cardiopulmonary testing to support exercise prescription, and define the metabolic profiles of post acute coronary syndrome.

  • Hidradenitis suppurativa treated with follicular unit excision: A prospective controlled 24-week pilot study

    This study is looking at follicular unit extraction to treat hidradenitis suppurativa, a condition that causes inflammation of hair follicles resulting in severe pain and scarring. Follicular unit extraction is a technique used in hair transplants to entirely remove hair follicles. We want to test whether or not by removing hair follicles using hair follicle extraction technique reduces inflammation and improve the quality of patients’ life. We will do hair follicle extraction on both sides of either the armpit or groin and compare it with topical routine treatments to assess whether or not there is improvement. We will follow the participants until week 24 of the study.

  • Evaluation of a novel co-designed ‘Fatigue-o-meter' to tackle post-stroke fatigue

    Post-stroke fatigue is a common and debilitating consequence of stroke, affecting over half of all stroke survivors, which can persist for years and interferes with recovery. Education is recommended but stroke survivors report that health professionals provide minimal information about fatigue that is difficult to apply to their daily life. This project will evaluate a co-designed education tool called the Fatigue-o-meter via a proof-of-concept study design.

  • Heart2Heart: Implementation of a peer support program for people with heart disease

    Heart2Heart is a community-based randomised controlled trial with 12 months follow-up. The aim of the study is to determine whether implementation of a digital peer support program for people living with CHD is effective in improving social connectedness, clinical and patient-reported outcomes and experience measures. The intervention group will have access to a 6-month intervention that enables peer support via an interactive mobile application, which includes online discussion groups, access to resources and facilitated conversations with health professionals. If effective, the digital peer support intervention has the potential to increase social connectedness and empower people to self-manage and support others through sharing lived experience and learning.

  • A pilot single-centre double-blind randomised controlled trial of the effect of centhaquine on stroke volume in the treatment of vasodilatory hypotension in adults admitted to the intensive care unit

    Current pharmacotherapy options of haemodynamic support in critically ill patients with vasodilatory hypotension are limited. Centhaquine is a novel agent that has a dual action on the sympathetic system and may helped in the management of hypotensive states. We hypothesise that, compared to placebo, centhaquine will be associated with higher stroke volume, higher central venous pressure, higher mean arterial pressure, and lower vasopressor agent use over six hours after initiation of the study infusion. We plan to enrol 18 adult patients.

  • The Bridging Study: Evaluating the Navicare service on mental health service access in regional Australia

  • Characterising and Tracking of Patients with Inherited Neurodegenerative Disorders (INDD)

    This project seeks to undertake a prospective longitudinal natural history study to generate a comprehensive phenotypic profile of biological, behavioural, clinical, neurocognitive and neurophysiological markers associated with INDD and its progression; and correlate with the genotype when clinically available. This work will provide more complete neurobiological descriptions, novel mechanistic insights, and clear recommendations regarding candidate biomarkers for diagnosis and treatment tracking.

  • Efficacy of transcutaneous spinal cord stimulation combined with locomotor training to improve walking ability in people with chronic spinal cord injury: a multi-centre double-blinded randomised sham-controlled trial (eWALK2.0)

    We will conduct a multi-centred, double-blind randomised sham-controlled trial on 88 people with chronic SCI. The primary outcome will be walking ability measured using the Two Minute Walk Test (2MWT) with stimulation. Participants will be randomised to either the Stimulation group or the Sham group. All participants will receive the same intensive locomotor training consisting of three thirty minute sessions per week, over 12 weeks, in combination with either stimulation or sham stimulation. The secondary outcomes will capture different aspects of recovery, strength, spasticity, and quality of life. Outcome measures will be taken at baseline, Day 0, 13-weeks and 6-months after randomisation. Our hypothesis is that spinal stimulation plus locomotor training in chronic SCI will improve walking ability, demonstrated by a clinically important change on the 2 Minute Walk test and that spinal stimulation will be a feasible and safe treatment that can be provided in a community setting.

  • An examination into the effects of Magtein on cognitive performance and sleep quality in young adults experiencing dissatisfied sleep

    In this randomised, double-blind, placebo-controlled study, 100 young-to-middle-aged adults aged 18 to 45 years with self-reported sleep difficulties will be randomly assigned to receive magnesium L-threonate (Magtein) or a placebo for 6 weeks. Changes in cognitive performance will be assessed at baseline and week 6 by administering The National Institutes of Health (NIH) Toolbox Cognition Battery and Raven’s Progressive Matrices Second Edition (Raven’s 2). Moreover, self-report questionnaires will be administered to examine changes in sleep quality, restorative sleep, and general wellbeing. Changes in sleep patterns will also be monitored using an Oura Ring. Finally, to measure potential changes in gaming skills, the 3D Aim Trainer, a first-person shooting game, will be administered at baseline and week 6.

Tags:
  • Finding clinical trials